Hidroclorotiazida Cinfa

Hidroclorotiazida Cinfa is a pharmaceutical product that contains the thiazide diuretic hydrochlorothiazide as its active ingredient. It is marketed in the European Union and supplied in an oral dosage form, although the specific tablet strength is not disclosed in the available data. The medication is prescription‑only, belongs to the antihypertensive and diuretic therapeutic classes, and is identified by ATC code C03AA03. It is intended for use under physician guidance.

Hydrochlorothiazide, the active component of Hidroclorotiazida Cinfa, is indicated for several conditions that involve excess fluid retention or elevated blood pressure.

- Hypertension (high blood pressure) - Edema associated with congestive heart failure - Edema due to renal disease (e.g., nephrotic syndrome) - Edema due to hepatic cirrhosis - Adjunct therapy with other antihypertensive agents when additional blood‑pressure control is needed

Like other thiazide diuretics, Hidroclorotiazida Cinfa may be associated with a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common: - Increased urinary frequency and volume - Mild electrolyte disturbances such as low potassium or sodium - Transient dizziness or light‑headedness, especially after standing - Elevated blood glucose levels in susceptible individuals - Slight increase in serum uric acid, potentially precipitating gout

Serious: - Severe electrolyte imbalance (e.g., hyponatremia, hypokalemia) leading to cardiac arrhythmias - Acute renal failure or significant rise in serum creatinine - Allergic reactions including rash, pruritus, or angioedema - Pancreatitis (rare)

Before initiating therapy with Hidroclorotiazida Cinfa, clinicians should evaluate several clinical factors to minimize risk and ensure appropriate use.

- Assess baseline blood pressure and renal function (serum creatinine, eGFR) - Monitor electrolyte levels, especially potassium, sodium, and magnesium - Use caution in patients with a history of gout or hyperuricemia - Avoid in individuals with severe hepatic impairment or anuria - Consider dose adjustment in elderly patients or those with reduced renal clearance - Review concomitant use of other diuretics or antihypertensive agents - Counsel patients about the need for regular laboratory monitoring

Hydrochlorothiazide can affect the pharmacokinetics or pharmacodynamics of several other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with lithium, which may increase lithium toxicity - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can reduce diuretic efficacy and impair renal function - Co‑administration with other thiazide or loop diuretics without medical supervision

Use with caution: - ACE inhibitors, ARBs, or beta‑blockers, as additive blood‑pressure lowering may cause hypotension - Antidiabetic agents, because thiazides can raise blood glucose levels - Anticoagulants, as volume depletion may enhance bleeding risk - Calcium‑supplementing agents, due to increased risk of hypercalcemia